Test Your Hypothesis

 BGPT Odds of True

High signal exclusivity and regional reporting skew are documented, but direct enrichment of exclusive SDRs for region-specific drugs has not been tested in the supplied evidence.

 Hypothesis Novelty

Cross-database SDR comparisons exist, but linking exclusivity to drug-region availability and deduplication artifacts is a relatively new framing.

 Quick Analysis Plan Copied

 Long Analysis Plan

What the evidence shows

Cross-database intersection analysis found 54.6% of 2,021,522 unique SDRs exclusive to one database; only 0.1% appeared in all four Cross-database SDR intersection study. The authors state these differences reflect reporting-system characteristics, not true clinical differences, and that no sensitivity analysis of deduplication thresholds was performed Deduplication sensitivity limitation.

Region-specific drug enrichment was not directly tested. VigiBase rivaroxaban reports were 55.3% US-origin Rivaroxaban US-origin concentration, and 94.2% of FAERS ixekizumab reports were US-origin Ixekizumab US report concentration, consistent with regional reporting skew — but the enrichment hypothesis requires a dedicated drug-region classification of the 1.1 million exclusive SDRs.

What is missing to disconfirm or confirm

• No supplied study stratified exclusive SDRs by drug marketing region or approval jurisdiction.
• Exclusivity could shift substantially with different Jaccard deduplication cutoffs, since content-based deduplication can over-deduplicate genuine reports or under-deduplicate residual overlap Content-based deduplication bias.

If exclusive signals persist for globally marketed drugs across all four databases, regional drug availability alone cannot explain exclusivity; conversely, strong regional enrichment would imply deduplication-driven exclusivity inflates perceived database-specific toxicities. Confidence: moderate — inference, not directly tested.